Literature DB >> 21843180

A decade of investment in radiotherapy in New South Wales: why does the gap between optimal and actual persist?

Michael B Barton1, Geoff P Delaney.   

Abstract

BACKGROUND: There is a gap between optimal and actual radiotherapy utilization (RTU) rates in New South Wales (NSW). It is uncertain if this is because these investments have been insufficient to meet demand, or demand has been over-estimated. In this study we assess trends in infrastructure, staffing and productivity in NSW over the last 10 years.
METHODS: The NSW Radiotherapy Management Information System reports annually on activity including new patients, new courses, retreatments, attendances, radiotherapy fields and Area Health Service (AHS) of residence. Data are obtained from interstate radiotherapy departments that treat NSW residents. A census of equipment and staffing is reported. RTU was defined as the number of new cases in a year treated by radiotherapy divided by the number of new cases of cancer in that year.
RESULTS: From 1999 to 2008, 115,941 NSW residents received at least one course of radiotherapy. During this time period there were 325,965 new diagnoses of cancer reported by the Central Cancer Registry. RTU was 38% in 1999 and in 2008. The number of linear accelerators increased from 34 to 42 between 1999 and 2008 but the number of accelerators per 1000 new cases of cancer remained static at 1.2. For AHSs, there was a significant relationship between more linear accelerators per 1000 patients and higher RTU (P = 0.0023).
CONCLUSION: Radiotherapy utilization in NSW has remained at 38% for the period 1999 to 2008 because investment in new facilities only just kept pace with the increase in the number of new cases of cancer with an indication for radiotherapy. Some regional AHS have shown significant increases in RTU with new facilities.
© 2011 The Authors. Journal of Medical Imaging and Radiation Oncology © 2011 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Year:  2011        PMID: 21843180     DOI: 10.1111/j.1754-9485.2011.02292.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Cross-institutional outcome prediction for head and neck cancer patients using self-attention neural networks.

Authors:  William Trung Le; Eugene Vorontsov; Francisco Perdigón Romero; Lotfi Seddik; Mohamed Mortada Elsharief; Phuc Felix Nguyen-Tan; David Roberge; Houda Bahig; Samuel Kadoury
Journal:  Sci Rep       Date:  2022-02-24       Impact factor: 4.379

2.  Factors affecting radiotherapy utilisation in geriatric oncology patients in NSW, Australia.

Authors:  Penny Mackenzie; Claire Vajdic; Geoff Delaney; Gabriel Gabriel; Meera Agar; Tracy Comans; Michael Barton
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-10-13

3.  Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia.

Authors:  Wsam Ghandourh; Lois Holloway; Vikneswary Batumalai; Phillip Chlap; Matthew Field; Susannah Jacob
Journal:  Clin Transl Radiat Oncol       Date:  2022-03-05

4.  Disparities in radiation therapy utilization for cancer patients in Victoria.

Authors:  Wee Loon Ong; Norah Finn; Luc Te Marvelde; Colin Hornby; Roger L Milne; Gerard G Hanna; Graham Pitson; Hany Elsaleh; Jeremy L Millar; Farshad Foroudi
Journal:  J Med Imaging Radiat Oncol       Date:  2022-03-31       Impact factor: 1.667

Review 5.  Provision and use of radiotherapy in Europe.

Authors:  Yolande Lievens; Josep M Borras; Cai Grau
Journal:  Mol Oncol       Date:  2020-05-01       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.